We would love to hear your thoughts about our site and services, please take our survey here.
Does feel its been suppressed - its basically same price as at end of the day of the cancer trial rns - after which it rose more partly on that news and then got a bit ramped all the way to 180. Since then a lot has happened and overall its been mostly good even if you dont like the ibs results. See this as climbing to at least 140 to 150 in next month or two just on entry to nasdaq, more if good news arrives.
Sold tesla at various points for varying profits. Kept what started as a measly 4k worth in wife's pension. Up over 1000 per cent now. Going to keep it as a kind of sadistic reminder not to sell winners too quickly (could easily have been a Tesla millionaire if Id stuck with the whole holding).
I agree. And all we can produce will probably be 100s millions by spring. They are likely to sign on very big manufacturers who will gravitate toward producing the best test. The ceo is very happy with performance of the test in evaluation with patients
Since we are not flies on the wall we can only guess the causes of delay. But I would say that the products will come in early feb and will be great. To avoid disappointment just add a month of contingency to that. Covid will still be a massive issue and we will have tests that will almost certainly help greatly and sell well. Stock will still be a tenner by Autumn
Sorry for misreading thimngs. A tweet by teaboy has shown they are making progress. Previous rns referred to about to test samples and then do larger evaluation with patients. It appears in last 4 weeks they both completed the study with samples and started evaluation with patients. We might well get rns in first 2 or 3 weeks of of jan saying patient evaluation complete, technical validation by bbi complete and clinical validation started. This would define an early feb timeline to market and if performance figures good bring an excellent relief rally.
I am in the mid camp. It would be valued at 50 to 70p but for placing and covid on expanded partnerships. Placing takes it up to 70 to 90 because it has cash runway to make faster and bigger impact in the clinic. From that you can guage that the market isnt ascribing much to covid - 20 to 40p. This amount is limited because of a combo of doubts on companys ability to deliver soon and market underestimation of both the quality of test to be produced and the length of runway of testing required. Its the market underestimation bits that make it a good stock to hold albeit a super frustrating one.
Yes jdt updating on covid test in new year mentioned and not same for ava which does potentially imply it will come before new year as planned. Covid test wise the rns a month ago referred to us evaluating both and this does the same. So BAMS evaluation was half way through a month ago and yet still not complete. And the initial evaluation of lfd was supposed to be small scale but not small enough to complete within 4 weeks clearly. Recently, I had cautioned on the timelines saying january was likely the business end. But every time you even make a conservative prediction with this company something makes a fool of you. I woke this morning thinking the cytiva connection likely caused a lot of the delays - look at what happened to the Canadian test they were involved with. Now I think its also part of the company mo that it struggles with delivery.